PND45 OCRELIZUMAB IS A COST-EFFECTIVE OPTION FOR RELAPSING...

Value in Health 2019 / 11 Vol. 22

PND45 OCRELIZUMAB IS A COST-EFFECTIVE OPTION FOR RELAPSING MULTIPLE SCLEROSIS PATIENTS, IN IRAN

Ayati, N., Sahraian, M.A., Taheri, S., Nikfar, S.
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
22
Journal:
Value in Health
DOI:
10.1016/j.jval.2019.09.1815
Date:
November, 2019
File:
PDF, 714 KB
2019
Conversion to is in progress
Conversion to is failed